Clinical Trial Update: Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra [Phase 1]

View source ↗

Summary

Phase 1 trial completed evaluating reversal of apixaban anticoagulation with four-factor prothrombin complex concentrate (Kcentra).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombosis

Drugs mentioned

• KCENTRA

Snippet

Sponsor: Thomas Jefferson University | Conditions: Thrombosis | Phase 1 | Status: COMPLETED